Weight Loss
GLP-1s, GIP agonists, and metabolic peptides.
About weight loss peptides
Weight-loss peptides are the most-researched compounds on VialVerdict, driven by the explosion of GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Research-grade versions of these compounds are widely available from peptide vendors, typically at a fraction of the prescription price.
Newer entrants — retatrutide (a triple agonist) and cagrilintide stacks — are showing even larger weight-loss effects in early trials. This category moves fast, so vendor reviews skew recent.
9 peptides in this category
Sorted by review volume — the compounds people are researching most.
Tirzepatide
Dual GIP/GLP-1 agonist. The current frontier for weight management research.
Semaglutide
The original blockbuster GLP-1. Widely available, well-studied, mainstream.
Retatrutide
The next-generation triple agonist. Showing the strongest weight-loss data in early trials.
Cagrilintide
Amylin analog researched alongside GLP-1s for appetite control and weight management.
AOD-9604
Modified HGH fragment researched for fat oxidation without affecting blood sugar.
HGH Fragment 176-191
Modified HGH fragment researched for fat oxidation without HGH side effects.
SLU-PP-332
ERR agonist researched as an exercise mimetic for fat loss and endurance.
Tesofensine
Centrally-acting compound researched for appetite suppression and significant weight reduction.
Survodutide
Boehringer's dual GLP-1 + glucagon agonist. Phase 3 weight-loss candidate showing strong fat-mass reductions.
What to know before buying
- Most weight-loss peptides ship as lyophilized vials and require refrigerated cold-chain shipping
- Look for vendors who pack with ice and publish HPLC test results per batch
- Side effects (nausea, fatigue) are very dose-dependent — start low, titrate slowly